Editorial: Unravelling real‐world impact of second‐line therapies in primary biliary cholangitis— Time to change our targets?-Reference-Cited by-同舟云学术

Editorial: Unravelling real‐world impact of second‐line therapies in primary biliary cholangitis— Time to change our targets?

Published:2024-05-21 Issue:1 Volume:60 Page:89-90
ISSN:0269-2813
Container-title:Alimentary Pharmacology & Therapeutics
language:en
Short-container-title:Aliment Pharmacol Ther

Author:

Cançado Guilherme Grossi Lopes¹²³

Affiliation:

1. Division of Gastroenterology and Hepatology, Toronto Centre for Liver Disease, Toronto General Hospital University Health Network Toronto Ontario Canada

2. Instituto Alfa de Gastroenterologia Hospital das Clínicas da Universidade Federal de Minas Gerais Belo Horizonte Brazil

3. Division of Gastroenterology and Hepatology Hospital da Polícia Militar de Minas Gerais Belo Horizonte Brazil

Abstract

LINKED CONTENTThis article is linked to Gomez et al papers. To view these articles, visit https://doi.org/10.1111/apt.18004 and https://doi.org/10.1111/apt.18048

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/apt.18032

Reference10 articles.

1. New Treatment Paradigms in Primary Biliary Cholangitis

2. Twenty-Year Comparative Analysis of Patients With Autoimmune Liver Diseases on Transplant Waitlists

3. Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis

4. Goals of Treatment for Improved Survival in Primary Biliary Cholangitis: Treatment Target Should Be Bilirubin Within the Normal Range and Normalization of Alkaline Phosphatase

5. Adequate versus deep response to ursodeoxycholic acid in primary biliary cholangitis: To what extent and under what conditions is normal alkaline phosphatase level associated with complication-free survival gain?

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Editorial: Unravelling real‐world impact of second‐line therapies in primary biliary cholangitis—Time to change our targets? Authors' reply;Alimentary Pharmacology & Therapeutics;2024-05-21